Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/19/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Renier J. Brentjens

Wrong Dr. Renier J. Brentjens?

Investigators

Phone: (212) ***-****  HQ Phone
Memorial Sloan-Kettering Cancer Center
1275 York Avenue Box # 460
New York, New York 10065
United States

Company Description: Memorial Sloan-Kettering Cancer Center is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
    SUNY Buffalo
  • PhD , microbiology
    SUNY Buffalo
76 Total References
Web References
Juno Therapeutics |
junotherapeutics.com, 19 Aug 2014 [cached]
DR. RENIER BRENTJENS
...
DR. RENIER BRENTJENS
Scientific co-founder
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens' lab has expanded this CAR technology to target additional tumor antigens.
More Info on Dr. Brentjens
...
Michel Sadelain and Renier J. Brentjens of Memorial Sloan Kettering Cancer Center, for winning the esteemed New York Intellectual Property Law Association (NYIPLA) "Inventor of the Year" award.
...
Sadelain and Brentjens were recognized for their extensive work in the design of chimeric antigen receptors (CARs).
Pictured: Isabelle Rivière, Michel Sadelain ...
www.mskcc.org, 20 July 2014 [cached]
Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
...
(From left) Investigators Isabelle Rivière, Michel Sadelain, and Renier Brentjens are founders of Juno Therapeutics.
...
Dr. Sadelain and two other Memorial Sloan Kettering researchers - Renier Brentjens, Director of Cellular Therapeutics, and Isabelle Rivière, Director of the Cell Therapy and Cell Engineering Facility - are playing a critical role in the formation of Juno and are founding scientists of the company. (All three researchers will continue in their roles at Memorial Sloan Kettering.)
...
Pictured: Renier J. Brentjens
...
Renier J. Brentjens - Researcher Profile
"Memorial Sloan Kettering was ...
www.eurekalert.org, 19 Feb 2014 [cached]
"Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients," said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study's senior authors.
...
Editor's note: Dr. Sadelain and Dr. Brentjens are co-holders of a patent that covers the technology used to create the modified T cells in this study.
Alexandria Summit: Oncology 2013
www.alexandriasummit.com, 18 Sept 2013 [cached]
Renier J. Brentjens, MD, PhD
Associate Member, Associate Attending Physician, Leukemia Service & Chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center
Renier J. Brentjens, MD, PhD, obtained an MD and PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service.
As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr. Brentjens became the principal investigator (PI) of his own laboratory.
As a PI, Dr. Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells, designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second-generation CAR modified T cell clinical trials. Additionally, work in Dr. Brentjens' lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors, including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen.
Renier J. Brentjens, MD, ...
www.targetedonc.com [cached]
Renier J. Brentjens, MD, PhD Published Online: March 12, 2014 Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Other People with the name "Brentjens":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.